Market

How Is Rentschler Biopharma Speeding Up Biologics in Asia?
Management & Regulatory How Is Rentschler Biopharma Speeding Up Biologics in Asia?

Imagine a region where the demand for life-changing biopharmaceuticals is skyrocketing, yet the race to deliver these treatments faster and more efficiently is becoming increasingly competitive. Asia, with its dynamic healthcare landscape, stands at the forefront of this challenge, particularly in

Siblings Launch First Black-Owned Telehealth for Black Women
Tech & Innovation Siblings Launch First Black-Owned Telehealth for Black Women

In a groundbreaking stride toward health equity, a pair of visionary sisters has introduced an innovative solution to address the longstanding disparities in healthcare for Black women, marking a significant milestone in medical accessibility. Dr. Jacqueline Philips and Lorraine Phillips have

How Does Avtozma IV Expand Treatment for Cytokine Release?
Management & Regulatory How Does Avtozma IV Expand Treatment for Cytokine Release?

Imagine a healthcare landscape where life-threatening conditions like cytokine release syndrome (CRS), triggered by immunotherapies or severe infections, can be managed with greater affordability and access. This vision is becoming a reality with the recent FDA approval of Celltrion’s Avtozma IV, a

How Will FDA PreCheck Strengthen US Drug Supply Chains?
Management & Regulatory How Will FDA PreCheck Strengthen US Drug Supply Chains?

In a landscape where over 50% of pharmaceuticals distributed in the US are manufactured overseas, the fragility of the drug supply chain has become a pressing concern for national health security, prompting urgent action. Imagine a scenario where a global crisis disrupts access to essential

Becton Dickinson's Earnings Boost Signals Med Device Strength
Management & Regulatory Becton Dickinson's Earnings Boost Signals Med Device Strength

In a landscape where economic volatility often shakes investor confidence, Becton Dickinson (BDX) has emerged as a standout performer, recently revising its full-year earnings outlook upward with an adjusted diluted EPS guidance of $14.30 to $14.45, reflecting a robust 9.4% growth at the midpoint.

Can AI-Discovered Rentosertib Transform IPF Treatment?
Tech & Innovation Can AI-Discovered Rentosertib Transform IPF Treatment?

The arena of idiopathic pulmonary fibrosis (IPF) treatment is witnessing a revolutionary phase with the advent of AI-driven solutions. AI stands as a groundbreaking force in reimagining drug discovery and development processes, taking significant strides in IPF treatment. Rentosertib, discovered

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later